43 results about "Cardiomyocyte apoptosis" patented technology

The invention relates to a compound as shown in the general formula I, or its isomer, medicinal salt and solvate; the invention also relates to a composition containing the compound as shown in the general formula I or its isomer, medicinal salt and solvate as well as a pharmaceutically acceptable carrier, excipient or diluent; the invention also relates to the usage of the compound as shown in the general formula I, or its isomer, medicinal salt and solvate in resisting cell apoptosis and preventing or treating diseases or symptoms related with cell apoptosis, especially to the usage in protecting cardiomyocytes and preventing or treating diseases or symptoms related with cardiomyocyte apoptosis.

The invention discloses two bromophenol compounds and a pharmaceutical application of their pharmaceutically-acceptable salts, specifically an application in the preparation of a myocardial ischemia-reperfusion injury protection drug. The two compounds and their pharmaceutically-acceptable salts can protect cardiomyocytes during rat heart acute ischemia so as to make rat heart functions complete.After routine intravenous administration, SOD activity after myocardial ischemia-reperfusion is raised, myocardial compliance is improved, serum LDH, serum CK, serum cTnT and MDA level after myocardial ischemia-reperfusion is remarkably reduced, myocardial injury is minimized, and FasmRNA after myocardial ischemia-reperfusion can be remarkably inhibited and reduced so as to inhibit cardiomyocyte apoptosis after myocardial ischemia-reperfusion. Therefore, the two bromophenol compounds and their pharmaceutically-acceptable salts have a clear myocardial ischemia-reperfusion injury protection function, thus providing a new method and means for the clinical treatment of myocardial ischemia-reperfusion injury and opening up a new direction for clinical medication.

The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate of the compound, and to a composition comprising the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents. The present invention also relates to use of the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, preventing or treating a disease or disorder associated with apoptosis; and especially use for protecting cardiomyocyte, and for preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.

The invention discloses application of a protosappanin A derivative in protecting cardiac trauma caused by chemotherapeutics. A chemical formula of the protosappanin A derivative is as shown in general formula I. Action and a mechanism of protecting cardiac trauma, induced by chemotherapeutics adriamycin, by the protosappanin A derivative are researched; research results show that the protosappanin A derivative can relieve cardiac trauma as well as myocardium cell apoptosis and oxidative stress injury induced by the adriamycin, and can be used as a heart protective drug. The invention discloses a novel and effective treatment way for treating or preventing cardiac trauma caused by chemotherapeutics.

The present invention relates to a compound of Formula (I), or an isomer, pharmaceutically acceptable salt and solvate thereof; the present invention further relates to a pharmaceutical composition, which comprises the compound of Formula (I), or isomer, pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents; the present invention further relates to the use of the compound of Formula (I), or isomer, pharmaceutically acceptable salt or solvate thereof, for anti-apoptosis, prophylaxis or treatment of a disease or symptom associated with apoptosis, especially for protecting myocardial cells, and prophylaxis or treatment of a disease or symptom associated with cardiomyocyte apoptosis.

The invention discloses the use of the alkaloid compound Hip in the preparation of a product for preventing and / or treating heart damage, the activity research of the alkaloid compound Hip is carried out, and it is verified that the alkaloid compound Hip provided by the invention can inhibit myocardial toxicity induced Apoptosis, by down-regulating the expression level of p-JNK and / or Cleaved-Caspase-3 to inhibit cardiomyocyte apoptosis induced by anthracycline drug DOX, thereby alleviating cardiomyocyte toxicity, and achieving prevention and / or treatment of cardiomyocyte toxicity The effect can be used to prepare medicines for preventing and / or treating diseases related to myocardial injury.

The invention discloses application of lysophosphatidic acid, a lysophosphatidic acid receptor 3 and a lysophosphatidic acid receptor 3 agonist and relates to the field of biomedicine. The study findsout that lysophosphatidic acid or the lysophosphatidic acid receptor 3 or the lysophosphatidic acid receptor 3 agonist can promote cardiomyocyte proliferation and inhibit cardiomyocyte apoptosis to repair damaged myocardia, significantly reduce myocardial infarct areas and significantly improve cardiac functions after myocardial infarction, and the effect is obvious. Therefore, lysophosphatidic acid, the lysophosphatidic acid receptor 3 and the lysophosphatidic acid receptor 3 agonist can be used in the field of preparation of medicine, preparations and the like for treating or preventing heart diseases, and new medicine and a new treatment idea are provided for treating or preventing heart diseases such as ischemic heart disease.

The invention relates a medicinal composition as well as a preparation method and applications of the medicinal composition. The medicinal composition is prepared from the following medicinal materials: herba agrimoniae, radix salviae miltiorrhizae, peach kernels, lignum dalbergiae odoriferae, radix ophiopogonis, rhizoma coptidis, radix scrophulariae, cortex moutan and leeches. Herba agrimoniae and radix salviae miltiorrhizae are taken as monarch drugs, peach kernels, lignum dalbergiae odoriferae and cortex moutan are taken as ministerial drugs, radix ophiopogonis, radix scrophulariae and leeches are taken as assistant drugs, the monarch drugs, the ministerial drugs and the assistant drugs perform the corresponding roles and are also matched with each other, and thus the medicinal composition has the efficacies of clearing Ying heat and eliminating toxins, promoting blood circulation to remove meridian obstruction, and strengthening the body resistance, especially has the functions of improving the cardiac function and the myocardial pathological form, promoting the angiogenesis, inhibiting the myocardium cell apoptosis, inhibiting the inflammatory reaction, protecting the endothelial cells, and the like, and has very good curative effects in treating or preventing coronary heart disease.

The invention discloses the application of doxycycline in the preparation of medicines for treating and / or preventing and / or alleviating and / or improving cardiomyopathy. The present invention applies doxycycline to the treatment of cardiomyopathy, which can restore cardiac diastolic function, reduce myocardial cell apoptosis and / or alleviate myocardial fibrosis, and alleviate cardiomyopathy, such as restrictive cardiomyopathy.

The present invention provides the application of miRNA708 and / or microRNA of cluster 301 in improving heart function. Specifically, microRNAs of miRNA708 and / or 301 clusters can (i) promote cardiomyocyte proliferation; (ii) improve cardiomyocyte anti-hypoxic stress ability; (iii) reduce cardiomyocyte apoptosis and death; (iv) induce myocardial cell proliferation; Proliferation and differentiation of stem cells; and / or (v) protecting cardiomyocytes from hypoxic stimulation.